Product Name: Rubella Virus–Like Particles
Catalog Number: ACVL-VLP008
Category: Virus-Like Particles (VLPs)
Expression System: HEK293 (Mammalian)
Protein Components: Capsid (C), E2 Glycoprotein, E1 Glycoprotein
Purity: ≥65% (densitometry)
Product Overview
Rubella Virus–Like Particles (VLPs) are recombinant, non-infectious particles that closely resemble the morphology and antigenic characteristics of native rubella virions. These VLPs are produced in HEK293 mammalian cells, enabling proper protein folding and post-translational modifications essential for maintaining native antigen conformation.
The particles are assembled from the viral structural proteins Capsid (C), envelope glycoprotein E2, and envelope glycoprotein E1, forming particulate structures that present conformational epitopes relevant for immune recognition. This makes them highly suitable for vaccine development, immunological studies, and assay applications.
Key Features
- Native-Like Antigen Presentation: Preserves conformational epitopes of rubella structural proteins for accurate immune recognition
- Mammalian Expression System: Ensures biologically relevant glycosylation and protein assembly
- Multicomponent Structure: Incorporates Capsid, E2, and E1 proteins for comprehensive antigen display
- Improved Immunogenic Potential: Demonstrates stronger immune responses compared to soluble protein antigens
- Non-Infectious Format: Free of viral genome, enabling safe handling in laboratory environments
Applications
- Vaccine research and preclinical development
- Immunogenicity and antigen evaluation
- Serological assay development (ELISA, neutralization assays)
- Antibody discovery and validation
- Viral structural and functional studies
Technical Specifications
| Item | Specification |
| Product Name | Rubella Virus–Like Particles |
| Catalog Number | ACVL-VLP008 |
| Expression System | HEK293 Mammalian Cells |
| Protein Components | Capsid (C), E2 Glycoprotein, E1 Glycoprotein |
| Purity | ≥65% (densitometry) |
| Formulation | 25 mM HEPES, 150 mM NaCl, 20% sucrose, pH 8.0 |
| Physical Form | Liquid |
| Storage | -80 °C recommended |
Biological Background
Rubella virus is an enveloped, positive-sense single-stranded RNA virus belonging to the genus Rubivirus within the family Togaviridae. The viral particle consists of a nucleocapsid core surrounded by a lipid envelope containing two key glycoproteins, E1 and E2.
E1 and E2 form heterodimeric complexes that are transported through the secretory pathway and displayed on the virion surface. Among these, E1 is the primary antigenic determinant responsible for eliciting neutralizing antibody responses. The coordinated expression of E1 and E2 is essential for proper protein folding, intracellular trafficking, and virion assembly.
Rubella VLPs retain the native structural organization of these proteins, enabling efficient stimulation of both humoral and cellular immune responses. Compared with soluble antigens, VLPs have been shown to induce stronger functional antibody responses, including virus-neutralizing activity.
Advantages for Vaccine Development
Rubella VLPs provide a robust platform for vaccine research due to their:
- Native-like structural presentation of viral antigens
- Ability to induce both B-cell and T-cell immune responses
- Favorable safety profile without replication risk
- Compatibility with scalable production systems
Customization & Bulk Supply
Flexible production and customization options are available to meet specific research and development needs, including formulation adjustment and scale-up manufacturing. Bulk supply inquiries are welcome.
Our products and services are for research use only and cannot be used for any clinical purposes.
